prof. Katrien Vandecasteele
- Work address
-
C. Heymanslaan 10, ingang 98 - verdieping 1
9000 Gent - Katrien.Vandecasteele@UGent.be
- ORCID iD
-
0000-0002-7221-0811
Show
Sort by
-
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial
(2022) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. In International Journal of Gynecological Cancer 32(Supplement 2). p.A187-A188 -
- Journal Article
- A1
- open access
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study
-
Impact of radiotherapy parameters on the risk of lymphopenia in urological tumors : a systematic review of the literature
-
- Journal Article
- A1
- open access
Association of cell death markers with tumor immune cell infiltrates after chemo-radiation in cervical cancer
-
- Journal Article
- A1
- open access
Mental health and quality of life among patients with cancer during the SARS-CoV-2 pandemic : results from the longitudinal ONCOVID survey study
-
- Journal Article
- A1
- open access
Safety of pre- or postoperative accelerated radiotherapy in 5 fractions : a randomized pilot trial
-
A clearer view on ovarian clear cell carcinoma
-
Impact of evaluation-decision form in lung cancer patients receiving stereotactic body radiotherapy
-
Radiotherapy for the vulvar region in frog-leg position : improving reproducibility and comfort.
-
Reducing overall treatment time, a pilot RCT of neo-adjuvant radiotherapy in early breast cancer